Enfortumab vedotin
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Enfortumab vedotin
May 12, 2024, 00:24 |
Insight
Karima Oualla: IBCG- AUA Bladder Cancer Forum
Karima Oualla, Professor of Medical Oncology at Hassan II University Hospital, shared a post on LinkedIn:…
Apr 30, 2024, 11:17 |
Insight
New Paper Alert! Targeting NECTIN4. Predicting Response to Enfortumab Vedotin in Metastatic Urothelial Cancer
Targeting NECTIN4. Predicting Response to Enfortumab Vedotin in Metastatic Urothelial Cancer Authors: Niklas Klümper, MD,…
Apr 27, 2024, 14:44 |
Insight
Aruni Ghose: Our review delves into the progress across urological malignancies and discusses future directions in ADC development
Aruni Ghose, Internal Medicine Resident at Barts Health NHS Trust, shared a post on LinkedIn:…
Apr 26, 2024, 17:55 |
Insight
Piotr Wysocki: NECTIN4 amplification is a predictive factor for enfortumab vedotin efficacy
Piotr Wysocki recently shared on LinkedIn: "Kluemper et al. published results of a study evaluating NECTIN4…
Apr 12, 2024, 12:37 |
Insight
Niklas Klümper: Happy to share our commentary about EV-302
Niklas Klümper, Resident in Urology and Researcher at the Institute for Experimental Oncology at the…
Mar 15, 2024, 15:26 |
Insight
Enfortumab+pembrolizumab combination as the 1st line treatment of choice for advanced urothelial cancer - summary by Piotr J. Wysocki
Piotr J. Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital,…
Feb 1, 2024, 17:24 |
Drugs
Day 2 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers shared on their X/Twitter: "Day 2 of GU24 ASCO Highlights 1. UNITE: EV…
Feb 1, 2024, 15:42 |
Opinion
Thomas Powles: Enfortumab Vedotin and Pembrolizumab shows broad spectrum of activity for Regional Recurrence, Progression-free survival and Overall Survival in all subgroups
Feb 1, 2024, 15:19 |
Opinion
Paolo Tarantino: Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared by Niklas…
Jan 31, 2024, 17:49 |
Insight
Earle Burgess: Initial results from a small pilot study in late mCRPC where there are limited to no effective treatment options available
Earle Burgess, Genitourinary Oncologist at Atrium Health Levine Cancer, shared on LinkedIn: "Enfortumab vedotin is…
1
2
All:
13
Posts:
1 - 10
OncoInfluencers: Dialogue with Rob Pieters, hosted by Shushan Hovsepyan
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Facebook
RSS Feed
Twitter
Linkedin
Youtube